Show simple item record

dc.contributor.authorOkine, Bright N.
dc.contributor.authorGaspar, Jessica C.
dc.contributor.authorFinn, David P.
dc.date.accessioned2020-11-02T10:33:31Z
dc.date.available2020-11-02T10:33:31Z
dc.date.issued2018-04-21
dc.identifier.citationOkine, Bright N, Gaspar, Jessica C, & Finn, David P. (2019). PPARs and pain. British Journal of Pharmacology, 176(10), 1421-1442. doi:10.1111/bph.14339en_IE
dc.identifier.issn0007-1188
dc.identifier.urihttp://hdl.handle.net/10379/16256
dc.description.abstractChronic pain is a common cause of disability worldwide and remains a global health and socio-economic challenge. Current analgesics are either ineffective in a significant proportion of patients with chronic pain or associated with significant adverse side effects. The PPARs, a family of nuclear hormone transcription factors, have emerged as important modulators of pain in preclinical studies and therefore a potential therapeutic target for the treatment of pain. Modulation of nociceptive processing by PPARs is likely to involve both transcription-dependent and transcription-independent mechanisms. This review presents a comprehensive overview of preclinical studies investigating the contribution of PPAR signalling to nociceptive processing in animal models of inflammatory and neuropathic pain. We examine current evidence from anatomical, molecular and pharmacological studies demonstrating a role for PPARs in pain control. We also discuss the limited evidence available from relevant clinical studies and identify areas that warrant further research.en_IE
dc.description.sponsorshipThis work was funded by grants from Science Foundation Ireland (10/IN.1/B2976), the Irish Research Council, CNPq - Conselho Nacional de Desenvolvimento Científico e Tecnológico, Brazil (207530/2014-9) and the National University of Ireland Galwayen_IE
dc.formatapplication/pdfen_IE
dc.language.isoenen_IE
dc.publisherWileyen_IE
dc.relation.ispartofBritish Journal Of Pharmacologyen
dc.rightsAttribution-NonCommercial-NoDerivs 3.0 Ireland
dc.rights.urihttps://creativecommons.org/licenses/by-nc-nd/3.0/ie/
dc.subjectACTIVATED-RECEPTOR-ALPHAen_IE
dc.subjectFATTY-ACID AMIDEen_IE
dc.subjectAUGMENTED PERIPHERAL INFLAMMATIONen_IE
dc.subjectATTENUATES TACTILE ALLODYNIAen_IE
dc.subjectSPINAL-CORD-INJURYen_IE
dc.subjectNEUROPATHIC PAINen_IE
dc.subjectRAT MODELen_IE
dc.subjectCONCISE GUIDEen_IE
dc.subjectANTIINFLAMMATORY ACTIVITIESen_IE
dc.subjectPERIAQUEDUCTAL GREYen_IE
dc.titlePPARs and painen_IE
dc.typeArticleen_IE
dc.date.updated2020-10-30T02:14:01Z
dc.identifier.doi10.1111/bph.14339
dc.local.publishedsourcehttps://bpspubs.onlinelibrary.wiley.com/doi/10.1111/bph.14339en_IE
dc.description.peer-reviewedpeer-reviewed
dc.contributor.funderScience Foundation Irelanden_IE
dc.contributor.funderIrish Research Councilen_IE
dc.contributor.funderConselho Nacional de Desenvolvimento Científico e Tecnológico, Brazilen_IE
dc.contributor.funderNational University of Ireland, Galwayen_IE
dc.internal.rssid16268809
dc.local.contactDavid Finn, Dept. Of Pharmacology &, Therapeutics, Nui, Galway. 5280 Email: david.finn@nuigalway.ie
dc.local.copyrightcheckedYes
dc.local.versionACCEPTED
dcterms.projectinfo:eu-repo/grantAgreement/SFI/SFI Principal Investigator Programme (PI)/10/IN.1/B2976/IE/The role of the endocannabinoid system in anxiety-induced modulation of pain: sites and mechanisms of action/en_IE
nui.item.downloads25


Files in this item

Thumbnail
Thumbnail

This item appears in the following Collection(s)

Show simple item record

Attribution-NonCommercial-NoDerivs 3.0 Ireland
Except where otherwise noted, this item's license is described as Attribution-NonCommercial-NoDerivs 3.0 Ireland